LOXO ONCOLOGY at Lilly

LY3295668

AURORA A KINASE INHIBITOR



Gong X, et al[1]; Goldenson B and Crispino JD[2]; Otto T and Sicinski P[3]; Rickman DS, et al[4]; Willems E, et al[5]

Target

Aurora kinases are believed to play a crucial role in cellular division by controlling chromosomal segregation. Defects in segregation can cause genetic instability, a condition highly associated with the formation of tumors. Aurora kinases—Aurora A, Aurora B, and Aurora C—are key mitotic regulators required for genome stability and are frequently overexpressed in cancerous tumors.

Molecule

LY3295668 has been shown in vitro and in vivo to be a highly selective Aurora A kinase inhibitor that targets cell-cycle dependency of sensitive tumors.[1]

Clinical Development

LY3295668 is being investigated in a clinical trial in patients with neuroblastoma.

References: 1. Gong X, et al. *Cancer Discov.* 2018. **2.** Goldenson B, Crispino JD. *Oncogene.* 2015;34(5):537-545. **3.** Otto T, Sicinski P. *Nat Rev Cancer.* 2017;17(2):93-115. **4.** Rickman DS, et al. *Cancer Discov.* 2018;8(2):150-163. **5.** Willems E, et al. *Cell Div.* 2018;13:7.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

NCT04106219

A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma*



* This clinical trial is being conducted globally.
† LY3295668 is administered PO.
‡ Cyclophosphamide is administered intravenously (IV).
§ Topotecan is administered IV.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

Key Inclusion Criteria

- Relapsed/refractory neuroblastoma and active disease in at least one of the following sites: bone, bone marrow, or soft tissue
- Must be able to submit an archival tissue sample
- Able to swallow capsules

Key Exclusion Criteria

- Prior hematopoietic stem cell, bone marrow, or solid organ transplant
- An untreated tumor that has spread to the brain or spinal cord
- A serious active disease other than neuroblastoma
- A condition affecting absorption
- Prior Aurora kinase inhibitor exposure
- Known allergy to the study treatment
- Symptomatic HIV or activated/reactivated hepatitis A, B, or C

LOXO ONCOLOGY at Lilly

Please visit **www.clinicaltrials.gov** for more information on this clinical trial [NCT04106219].

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

LOXO ONCOLOGY at Lilly

Pipeline information is current through April 27, 2021.